Real-World study tracks palbociclib use in canadian breast cancer patients

NCT ID NCT06003114

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This study observes how Canadian women with a specific type of advanced breast cancer (HR+/HER2-) use the drug palbociclib (Ibrance) as their first treatment. Researchers will measure how long patients stay on the drug and look at treatment patterns in real-world settings, outside of a controlled clinical trial. The goal is to better understand how this medication is actually used in everyday practice.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
palbociclib (Ibrance)
What this could lead to
If successful, this study could reveal how well palbociclib works outside of clinical trials, helping doctors optimize treatment for women with this type of breast cancer.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by patient selection and real-world variability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Alberta Health Services

    Edmonton, Alberta, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.